| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... The Lancet 376 (9742), 687-697, 2010 | 7816 | 2010 |
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... The Lancet 383 (9911), 31-39, 2014 | 2362 | 2014 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1130 | 2018 |
| Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease K Qureshi, GA Abrams World journal of gastroenterology: WJG 13 (26), 3540, 2007 | 887* | 2007 |
| Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species MG Perrelli, P Pagliaro, C Penna World journal of cardiology 3 (6), 186, 2011 | 444 | 2011 |
| ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... Lancet 376 (9742), 687-697, 2010 | 353 | 2010 |
| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 345 | 2019 |
| Assessment of a HER2 scoring system for colorectal cancer: results from a validation study E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ... Modern Pathology 28 (11), 1481-1491, 2015 | 281 | 2015 |
| Clinical advances in the development of novel VEGFR2 inhibitors C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ... Annals of translational medicine 2 (12), 2014 | 265 | 2014 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 254 | 2020 |
| New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury M Cinausero, G Aprile, P Ermacora, D Basile, MG Vitale, V Fanotto, ... Frontiers in pharmacology 8, 354, 2017 | 250 | 2017 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 226 | 2019 |
| BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ... Annals of oncology 26 (10), 2092-2097, 2015 | 195 | 2015 |
| Peripheral blood markers identify risk of immune‐related toxicity in advanced non‐small cell lung cancer treated with immune‐checkpoint inhibitors A Pavan, L Calvetti, A Dal Maso, I Attili, P Del Bianco, G Pasello, ... The oncologist 24 (8), 1128-1136, 2019 | 188 | 2019 |
| BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ... British journal of cancer 112 (12), 1921-1928, 2015 | 173 | 2015 |
| Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction … K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, ... The Lancet 401 (10389), 1655-1668, 2023 | 153 | 2023 |
| REGARD Trial Investigators Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... Lancet 383 (9911), 31-39, 2014 | 140 | 2014 |
| Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions F Puglisi, C Zuiani, M Bazzocchi, F Valent, G Aprile, B Pertoldi, ... Oncology 65 (4), 311-315, 2003 | 137 | 2003 |
| Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 … F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ... Cancer 122 (4), 574-581, 2016 | 135 | 2016 |
| Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective … A Russo, M Russano, T Franchina, MR Migliorino, G Aprile, G Mansueto, ... Advances in therapy 37, 1145-1155, 2020 | 134 | 2020 |
daniele santiniprofessor in general pathologyПодтвержден адрес электронной почты в домене unicampus.it
